Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics' stock price has decreased by 31.21% over the past six months and 9.22% in the past month. The company reported its fourth quarter and full-year 2025 financial results on March 27, 2026. In 2025, Monopar strengthened its balance sheet through an underwritten public offering, generating approximately $91.9 million. Recent insider trading activity has shown a net sell-off by insiders, with a total transaction value of -$238,964, although there was a net buy of $104,925 from executives.

Based on historical data, Monopar Therapeutics Inc. - Common Stock exhibits some seasonal patterns. September has been the strongest month for the stock, with an average return of 49.72% and a win rate of 33%. August tends to be the weakest month, with an average return of -15.53%.

Monopar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapeutics and a treatment for Wilson Disease. The company operates in the Healthcare sector, specifically in the Biotechnology & Medical Research industry, utilizing both in-house development and the licensing/acquisition of therapeutics. Its product pipeline includes MNPR-101-Zr, a clinical-stage uPAR-targeted radiodiagnostic imaging agent; MNPR-101-RIT, a late preclinical stage radiotherapeutic; Camsirubicin (MNPR-201), a Phase 1b clinical stage analog of doxorubicin; MNPR-202, an early-stage analog of camsirubicin; ALXN1840, a late-stage investigational medicine for Wilson Disease; MNPR-101-Lu, a Phase 1a stage radiotherapeutic; and MNPR-101-Ac, a late-preclinical stage radiotherapeutic.

Monopar Therapeutics Inc. develops cancer therapeutics in the United States. The company is headquartered in Wilmette, Illinois, and its team operates out of Chicago, IL.

Monopar Therapeutics generally holds a positive reputation among analysts, with a consensus "Buy" rating. Thirteen analysts have rated the company, with ten recommending "buy" and two issuing a "strong buy" rating, while one analyst has rated the stock with a "sell" rating. The average 12-month price target among brokerages is $107.00. Recent news and business updates contribute to the company's public profile.

Monopar Therapeutics Inc. has significant institutional ownership, with 85 institutional owners and shareholders holding 5,389,154 shares, representing 82.64% of the stock. Major institutional shareholders include Janus Henderson Group Plc, Ra Capital Management, L.p., and Vanguard Group Inc. Arthur J. Klausner is the largest individual shareholder, owning 9.17 million shares, representing 137.30% of the company. Insiders collectively own approximately 287.67% of the company.